Quick10K

⚲

Accelerate Diagnostics

Filings

10-Q	2020-06-30	Filed 2020-08-10
10-Q	2020-03-31	Filed 2020-05-08
10-K	2019-12-31	Filed 2020-02-28
10-Q	2019-09-30	Filed 2019-11-08
10-Q	2019-06-30	Filed 2019-08-08
10-Q	2019-03-31	Filed 2019-05-10
10-K	2018-12-31	Filed 2019-03-01
10-Q	2018-09-30	Filed 2018-11-06
10-Q	2018-06-30	Filed 2018-08-07
10-Q	2018-03-31	Filed 2018-05-10
10-K	2017-12-31	Filed 2018-03-01
10-Q	2017-09-30	Filed 2017-11-07
10-Q	2017-06-30	Filed 2017-08-07
10-Q	2017-03-31	Filed 2017-05-05
10-K	2016-12-31	Filed 2017-02-28
10-Q	2016-09-30	Filed 2016-11-09
10-Q	2016-06-30	Filed 2016-08-08
10-Q	2016-03-31	Filed 2016-05-10
10-K	2015-12-31	Filed 2016-03-09
10-Q	2015-09-30	Filed 2015-11-02
10-Q	2015-06-30	Filed 2015-07-31
10-Q	2015-03-31	Filed 2015-05-07
10-K	2014-12-31	Filed 2015-02-26
10-Q	2014-09-30	Filed 2014-11-04
10-Q	2014-06-30	Filed 2014-08-01
10-Q	2014-03-31	Filed 2014-05-02
10-K	2013-12-31	Filed 2014-03-07
10-Q	2013-09-30	Filed 2013-11-08
10-Q	2013-06-20	Filed 2013-08-09
10-Q	2013-03-31	Filed 2013-05-10
10-Q	2012-10-31	Filed 2012-12-14
10-K	2012-07-31	Filed 2012-10-26
10-Q	2012-04-30	Filed 2012-06-13
10-Q	2012-01-31	Filed 2012-03-15
10-Q	2011-10-31	Filed 2011-12-14
10-K	2011-07-31	Filed 2011-10-27
10-Q	2011-04-30	Filed 2011-06-14
10-Q	2011-01-31	Filed 2011-03-16
10-Q	2010-10-31	Filed 2010-12-14
10-K	2010-07-31	Filed 2010-09-16
10-Q	2010-04-30	Filed 2010-06-14
10-Q	2010-01-31	Filed 2010-03-17

Reports

8-K	2020-08-18	Other Events, Exhibits
8-K	2020-06-29	Officers
8-K	2020-06-22	Officers
8-K	2020-05-08
8-K	2020-05-04
8-K	2020-04-15
8-K	2020-04-14
8-K	2020-03-24
8-K	2020-02-27
8-K	2020-01-31
8-K	2020-01-13
8-K	2019-12-20
8-K	2019-12-01
8-K	2019-11-07
8-K	2019-10-31
8-K	2019-08-20
8-K	2019-08-02
8-K	2019-05-10
8-K	2019-05-09
8-K	2019-02-19
8-K	2019-01-06
8-K	2018-12-21
8-K	2018-12-04
8-K	2018-11-06
8-K	2018-09-25
8-K	2018-08-06
8-K	2018-05-09
8-K	2018-05-03
8-K	2018-03-22
8-K	2018-02-15
8-K	2018-01-10

Accelerate Diagnostics Financials

AXDX Metrics, Comps, Filings

Quarterly | Annual

Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Equity

Income Statement ($BB Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($BB Quarterly)

Ops, Inv, Fin


Comps ($MM TTM)	Market Cap	Gross Margin	EV/EBITDA	Ret on Assets	Assets	Liabilities	Revenue	G Profit	Net Income	EBITDA	EV
Illumina (ILMN)	44,722	69%	35.1	14%	7,089	2,650	3,458	2,395	973	1,255	44,038
Agilent Technologies (A)	24,292	54%	18.0	9%	9,452	4,704	5,163	2,805	877	1,368	24,690
Mettler Toledo (MTD)	17,554	58%	26.5	21%	2,636	2,198	2,983	1,720	550	700	18,558
Waters (WAT)	15,473	18%	31.8	15%	2,561	2,446	2,405	428	392	513	16,324
Bio-Rad Laboratories (BIO)	10,341	55%	12.0	5%	7,177	2,046	2,304	1,259	377	850	10,215
PerkinElmer (PKI)	9,500	48%	25.3	4%	6,489	3,782	2,835	1,374	234	449	11,362
Bruker (BRKR)	6,836	48%	23.2	9%	2,352	1,507	2,026	972	207	305	7,055
Coherent (COHR)	3,296	34%	37.6	3%	2,083	798	1,431	486	54	79	2,977
Accelerate Diagnostics (AXDX)	1,034	45%	-15.4	-58%	147	137	8	3	-85	-72	1,112
Pacific Biosciences of California (PACB)	862	33%	-7.4	-79%	146	95	82	27	-115	-113	840
Fluidigm (FLDM)	852	40%	-16.2	-19%	269	107	117	46	-52	-51	824
Quanterix (QTRX)	607	39%	-12.8	-22%	176	39	52	20	-39	-39	501
EyePoint Pharmaceuticals (EYPT)	194	67%	-2.9	-101%	79	63	12	8	-80	-72	209
Harvard Bioscience (HBIO)	130	55%	33.8	-1%	163	86	119	66	-2	5	175
HTG Molecular Diagnostics (HTGM)	36	48%	0.2	-29%	51	23	14	7	-15	-13	-2
Precipio (PRPO)	20	4%	-2.2	-42%	23	7	6	0	-9	-9	19
Astrotech (ASTC)	11	17%	-1.4	-144%	5	4	0	0	-7	-7	10
Bionano Genomics (BNGO)	7	29%	0.1	-81%	19	27	11	3	-16	-13	-1
Aethlon Medical (AEMD)	0	0%	0.1	-579%	1	1	0	0	-7	-7	-0


Balance Sheet ($MM)	2011-10-31	2012-01-31	2012-04-30	2012-07-31	2012-10-31	2013-03-31	2013-06-20	2013-09-30	2013-12-31	2014-03-31	2014-06-30	2014-09-30	2014-12-31	2015-03-31	2015-06-30	2015-09-30	2015-12-31	2016-03-31	2016-06-30	2016-09-30	2016-12-31	2017-03-31	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30	2018-12-31	2019-03-31	2019-06-30	2019-09-30
Cash	1	1	0	14	13	29	27	33	30	26	65	58	54	47	35	25	121	72	38	29	19	10	63	34	29	127	67	62	66	75	87	93
Accounts Receivable
Inventory	0	0	0	0	0								1									4	6	7	8	10	11	9	8	9	8	8
PP&E	0	0	0	0	0	1	1	1	1	2	3	3	4	5	6	6	8	8	9	9	9	9	11	11	11	13	13	16	16	16	17	19
Assets	6	6	6	17	16	31	29	46	43	41	82	75	70	63	53	45	139	126	111	97	83	74	148	136	126	213	218	201	185	172	159	147
Accounts Payable	0	0	0	0	0	0	0	0	1	1	1	1	2	2	2	2	3	3	2	2	1	1	2	1	2	3	2	2	1	3	2	2
Long-Term Debt										0	0	0	0	0	0	0	0									99				172	172	172
Liabilities	2	2	2	2	2	1	2	1	2	3	3	3	4	5	4	5	6	6	5	5	5	5	6	6	7	107	123	123	128	129	133	137
Stockholders' Equity	5	4	4	15	13	30	28	45	42	39	79	72	66	59	49	40	133	120	105	91	78	69	142	130	119	106	95	77	57	43	26	10


Income Statement ($MM)	2011-10-31	2012-01-31	2012-04-30	2012-07-31	2012-10-31	2013-03-31	2013-06-20	2013-09-30	2013-12-31	2014-03-31	2014-06-30	2014-09-30	2014-12-31	2015-03-31	2015-06-30	2015-09-30	2015-12-31	2016-03-31	2016-06-30	2016-09-30	2016-12-31	2017-03-31	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30	2018-12-31	2019-03-31	2019-06-30	2019-09-30
Revenue	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	2	1	2	1	2	2	2	2
Cost of Revenue																						0	0	0	1	0	1	1	1	1	1	1
Gross Profit																						1	1	1	1	0	1	1	1	1	1	1
R&D	0	0	0	0	1	2	4	3	4	4	5	6	6	6	7	6	6	7	8	8	5	4	6	6	6	7	6	8		7	6	6
SG&A	0	0	0	2	1	1	1	1	1	2	4	3	3	3	5	4	6	7	9	9	10	11	11	12	11	14	15	12		13	13	13
Tax														1	0	0							0	0	0	0	0	0		0	0	-0
Net Income	-0	-0	-0	-4	-2	-3	-4	-4	-5	-5	-8	-9	-9	-9	-12	-11	-13	-15	-18	-17	-16	-14	-16	-17	-16	-21	-23	-22	-22	-22	-20	-20


Cash Flow ($MM)	2011-10-31	2012-01-31	2012-04-30	2012-07-31	2012-10-31	2013-03-31	2013-06-20	2013-09-30	2013-12-31	2014-03-31	2014-06-30	2014-09-30	2014-12-31	2015-03-31	2015-06-30	2015-09-30	2015-12-31	2016-03-31	2016-06-30	2016-09-30	2016-12-31	2017-03-31	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30	2018-12-31	2019-03-31	2019-06-30	2019-09-30
Cash Operating	-0	-0	-0	-0	-1	-2	-3	-3	-3	-4	-4	-6	-5	-7	-9	-9	-10	-13	-15	-13	-13	-15	-13	-14	-13	-16	-19	-18		-20	-14	-17
Cash Investing	-0	-0	-0	-0	-0	-1	-1	-11	-1	-1	-2	-1	0	1	-3	-1	1	-34	-21	3	3	4	-20	-15	5	12	-63	12		25	25	21
Cash Financing					0	20	20	20	0	1	45	-0	0	0	0	0	104	-1	1	1	1	2	85	1	2	102	23	1		4	1	2